华润医药(03320.HK) 公布，旗下附属公司华润博雅生物截至今年3月底止首季度业绩，营业总收入5.36亿元人民币(下同)，按年升19.5%；净利润1.39亿元，按年跌8.2%。(js/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-24 16:25。)
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2025/03/26 | 末期业绩 | 股息：人民币 0.0520 (约相等于 0.056 港元, 可选择港币或该等货币组合) |
| 2024/08/29 | 中期业绩 | 股息：人民币 0.0830 (约相等于 0.0908 港元, 可选择港币或该等货币组合) |
| 2024/03/26 | 末期业绩 | 股息：人民币 0.1540 (约相等于 0.1697 港元, 可选择HKD或该等货币组合) |
| 2023/08/31 | 中期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.